Article
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Blood - 1 Jun 2007
Gouw Samantha C, van der Bom Johanna G, Auerswald Günter, Ettinghausen Carmen Escuriola, Tedgård Ulf, van den Berg H Marijke
Abstract excerpt
It has been suggested that plasma-derived factor VIII products induce fewer inhibitors than recombinant factor VIII products. We investigated the relationship of factor VIII product type and switching between factor VIII products with the risk to develop inhibitors. This multicenter retrospective cohort study included 316 patients with severe hemophilia A born between 1990 and 2000. The outcome was clinically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.